Skip to main content

Table 2 Primers used for quantitative polymerase chain reaction assay

From: Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study

Primer

Sequence

Annealing temperature (°C)

Expected product size (bp)

CC10

[S] 5'-GGACACACCCTCCAGTTATGA-3'

60

126

[A] 5'-ATGATGCTTTCTCTGGGCTTT-3'

IL-33

[S] 5'-ACAGCAAAGTGGAAGAACACAG-3'

60

162

[A] 5'-CCTTTTGGTGGTTTCTCTCCTA-3'

TSLP

[S] 5’-CCCAGGCTATTCGGAAACTCA-3’

60

118

[A] 5'-ACGCCACAATCCTTGTAATTGTG-3'

IL-25

[S] 5'-AAGGAGATGGTTGGTCAGAAGA-3'

58

182

[A] 5'-CTCCTAATCGCAAAAGAGCATC-3'

Osteopontin

[S] 5'-CAACCGAAGTTTTCACTCCAG-3'

58

173

[A] 5'-ATTCAACTCCTCGCTTTCCAT-3'

CCL20/MIP-3α

[S] 5'-GAATCAGAAGCAGCAAGCAAC-3'

60

209

[A] 5'-TTTTTACTGAGGAGACGCACAA-3'

CXCL19/MIG

[S] 5'-GTTCTTTTCCTCTTGGGCATC-3'

60

108

[A] 5'-GATAGTCCCTTGGTTGGTGCT-3'

CCL17/TARC

[S] 5'-GCCCCACTGAAGATGCTG-3'

60

204

[A] 5'-GCCCTGCACAGTTACAAAAAC-3'

CCL22/MDC

[S] 5'-TGATTACGTCCGTTACCGTCT-3'

60

179

[A] 5'-AGTAGGCTCTTCATTGGCTCA-3'

CXCL5/ENA-78

[S] 5'-TTACAGACCACGCAAGGAGTT-3'

60

105

[A] 5'-GTTCTTCAGGGAGGCTACCAC-3'

ECP

[S] 5'-TGCCCTCATAACAGAACTCTCA-3'

60

216

[A] 5'-GATGGTGGTATCCAGGTGAACT-3'

MDA-5

[S] 5'-GTTTGGCAGAAGGAAGTGTCA-3'

60

213

[A] 5'-CTGTAGGGAGGCAGATGATGA-3'

TLR2

[S] 5'-ATGCTGCCATTCTCATTCTTCT-3'

60

101

[A] 5'-CTCCAGGTAGGTCTTGGTGTTC-3'

TLR3

[S]5'-CGCTAAAAAGTGAAGAACTGGA-3'

60

100

[A]5'-TGAAAACACCCTGGAGAAAACT-3'

TLR4

[S] 5'-CTTCTCAACCAAGAACCTGGAC-3'

60

158

[A] 5'-TAGAGAGGTGGCTTAGGCTCTG-3'

TLR9

[S] 5'-CTACAACCGCATCGTCAAACT-3'

60

217

[A] 5'-ATTCAGCCAGGAGAGAGAACTG-3'

EGF

[S] 5'-CTCATCACTGGTTGTGGTTCAT-3'

60

133

[A] 5'-CATAAAACCTTCACGACACGAA-3'

MMP9

[S] 5'-ACCACCACAACATCACCTATTG-3'

60

166

[A] 5'-ACACCAAACTGGATGACGATG-3'

TGF-β1

[S] 5'-CAGCAACAATTCCTGGCGATA-3'

57

136

[A] 5'-AAGGCGAAAGCCCTCAATTT-3'

CD86

[S] 5'-CAGCCTCTTCTTCTCTCAGCAG-3'

60

100

[A] 5'-CTCACTGGGGTCTGTGGTCT-3'

OX40L

[S] 5'-AAATGAAGAGGAGCAAGGAGTG-3'

60

247

[A] 5'-CTGGGAAAGCAAAATGGTAAAG-3'

ICOSL

[S] 5'-AGGTTTTGAGCGTTGAGGTTAC-3'

60

165

[A] 5'-GGCTGTTGTCCGTCTTATTGAT-3'

PD-L1

[S] 5'-GAACTACCTCTGGCACATCCTC-3'

60

126

[A] 5'-CACATCCATCATTCTCCCTTTT-3'

CD80

[S] 5'-TAATAAGCAAAGGGAGCACTGG-3'

60

140

[A] 5'-GCACAGGAGTCTGATGAACAAA-3'

GAPDH

[S] 5'-ACCCAGAAGACTGTGGATGG-3'

61

201

[A] 5'-TTCTAGACGGCAGGTCAGGT-3'

  1. CC10, Clara cell 10-kD protein; IL, interleukin; TSLP, thymic stromal lymphopoietin; CCL, CC chemokine ligand; MIP-3α, macrophage inflammatory protein-3α; CXCL, CXC chemokine ligand; MIG, monokine induced by interferon-γ; TARC, thymus and activation-regulated chemokine; MDC, macrophage-derived chemokine; ENA-78, epithelial neutrophil-activating peptide-78; ECP, eosinophilic cationic protein; MDA-5, melanoma differentiation-associated gene 5; TLR, Toll-like receptor; EGF, epidermal growth factor; MMP9, matrix metalloproteinase 9; TGF-β1, transforming growth factor-β1; OX40L, OX40 ligand; ICOSL, inducible costimulator ligand; PD-L1, programmed cell death ligand 1; GAPDH, glyceraldehydes-3-phosphate dehydrogenase